TRAF6 and melanoma: Since RSK is involved in the control of mRNA translation and is also a potent modulator of inflammation through the TRAF6-IKK-NF-κB pathway (Zhang et al, 2005; Peng et al, 2010; Yao et al, 2018), we hypothesize that RSK inhibition in melanoma may globally reduce the bioenergetic charge and associated oxidative stress in melanoma cells.